Latent Hazard in Prostate Cancer and Benign Prostatic Hyperplasia Patients Referred to Antiandrogens: Prostate Cancer Aggressiveness and Neuroendocrine Differentiation

    January 2004 in “ Anticancer Research ”
    Marko Tarle, Iva Petek, Sunčica Novosel, Zaky Ahel, Zvonko Kusić
    TLDR Long-term antiandrogen use may increase aggressive prostate cancer risk.
    The study indicated that prolonged antiandrogen therapy, such as finasteride treatment for BPH, could lead to intraprostatic DHT deficiency and potentially provoke neuroendocrine (NE) differentiation within the prostate. This NE differentiation was identified as a risk factor for developing aggressive prostate cancer. The research aimed to clarify the cancer development hazard in BPH patients treated with finasteride.
    Discuss this study in the Community →